Dendreon (DNDN) Appoints Several New Executives; Joe DePinto Joins as Commercial Ops EVP
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Join SI Premium – FREE
Dendreon Corporation (Nasdaq: DNDN) announced three new appointments to the Company’s executive team. Joe DePinto is joining Dendreon as executive vice president, global commercial operations; Robert S. Poulton, currently global head of quality, has been appointed executive vice president, technical operations; and Christine Mikail is joining Dendreon as executive vice president, corporate development, general counsel, and secretary. Mr. DePinto, Mr. Poulton and Ms. Mikail will report to John H. Johnson, president and chief executive officer. All three appointments are effective immediately.
DePinto will be responsible for all sales, marketing, and market access teams in the U.S. and globally. He has spent the last two decades commercializing and developing oncology products. Mr. DePinto’s experience includes sales, marketing, strategic accounts, market access, and product development on the R&D side. Mr. DePinto’s commercial expertise will help build upon Dendreon’s solid foundation for successfully selling PROVENGE® (sipuleucel-T) in the U.S. Mr. DePinto most recently was vice president and product champion for ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company and previously served as vice president, U.S. sales and marketing at Abraxis Bioscience. Prior to that, Mr. DePinto served as vice president, commercial operations at ImClone Systems; global Marketing Leader, Oncology Therapeutics for Johnson & Johnson Pharmaceutical Services Inc.; and vice president, oncology sales at Ortho Biotech Products. Mr. DePinto earned his Bachelor of Science in Marketing and MBA in Pharmaceutical Chemical Studies from Fairleigh Dickinson University.
Mr. Poulton brings more than two decades of manufacturing and operational experience to the executive team, having previously served Dendreon as its global head of quality. In this new role, Mr. Poulton will oversee Dendreon’s global manufacturing, operations, logistics and quality functions. Prior to joining Dendreon in 2010, Mr. Poulton served in a number of senior positions at Wyeth, including senior vice president, CMC, Compliance and Conformance, group vice president of global strategy, technical operations; group vice president of international operations and technology, and senior vice president of international operations and supply chain. While there, he was responsible for transforming the Wyeth Global Supply Chain. Before that, Mr. Poulton spent more than 19 years at SmithKline Beecham overseeing quality functions around the world. Following the merger of SmithKline Beecham and GlaxoWellcome, Mr. Poulton was appointed vice president of worldwide regulatory compliance, responsible for all R&D regulated facilities and processes. Born in the United Kingdom, Mr. Poulton graduated with a First Class Honours degree in Applied Chemistry from Brighton Polytechnic.
Ms. Mikail will be responsible for legal, corporate development, and government affairs at Dendreon. She has experience in high-growth business development, complex transaction structuring and negotiation, intellectual property and patent portfolio management, regulatory and clinical strategy, as well as public company representation. Ms. Mikail most recently served as senior vice president, corporate development at Savient Pharmaceuticals. Prior to that, Ms. Mikail served as vice president, general counsel and secretary for ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, as well as a member of Eli Lilly’s Transactions Center of Expertise. Previously, Ms. Mikail worked at the law firms of Reed Smith LLP, Lowenstein Sandler PC and Wilmer Hale. Ms. Mikail earned her Bachelor of Arts from Rutgers University and J.D. from Fordham University School of Law.
Ms. Mikail succeeds John E. Osborn, who will remain with Dendreon to assist in the transition and provide advice to Mr. Johnson on selected matters. Mr. Osborn also will be teaching at the University of Washington and serving as a member of the healthcare innovation policy group for the Romney presidential campaign. "We’re grateful to John for his contributions. John joined the company in a critical transitional period following our launch of PROVENGE, and he provided valuable strategic advice and counsel to me and the Board of Directors, while working to strengthen our legal, compliance and policy functions," said Mitchell H. Gold, executive chairman of the Board of Directors.
DePinto will be responsible for all sales, marketing, and market access teams in the U.S. and globally. He has spent the last two decades commercializing and developing oncology products. Mr. DePinto’s experience includes sales, marketing, strategic accounts, market access, and product development on the R&D side. Mr. DePinto’s commercial expertise will help build upon Dendreon’s solid foundation for successfully selling PROVENGE® (sipuleucel-T) in the U.S. Mr. DePinto most recently was vice president and product champion for ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company and previously served as vice president, U.S. sales and marketing at Abraxis Bioscience. Prior to that, Mr. DePinto served as vice president, commercial operations at ImClone Systems; global Marketing Leader, Oncology Therapeutics for Johnson & Johnson Pharmaceutical Services Inc.; and vice president, oncology sales at Ortho Biotech Products. Mr. DePinto earned his Bachelor of Science in Marketing and MBA in Pharmaceutical Chemical Studies from Fairleigh Dickinson University.
Mr. Poulton brings more than two decades of manufacturing and operational experience to the executive team, having previously served Dendreon as its global head of quality. In this new role, Mr. Poulton will oversee Dendreon’s global manufacturing, operations, logistics and quality functions. Prior to joining Dendreon in 2010, Mr. Poulton served in a number of senior positions at Wyeth, including senior vice president, CMC, Compliance and Conformance, group vice president of global strategy, technical operations; group vice president of international operations and technology, and senior vice president of international operations and supply chain. While there, he was responsible for transforming the Wyeth Global Supply Chain. Before that, Mr. Poulton spent more than 19 years at SmithKline Beecham overseeing quality functions around the world. Following the merger of SmithKline Beecham and GlaxoWellcome, Mr. Poulton was appointed vice president of worldwide regulatory compliance, responsible for all R&D regulated facilities and processes. Born in the United Kingdom, Mr. Poulton graduated with a First Class Honours degree in Applied Chemistry from Brighton Polytechnic.
Ms. Mikail will be responsible for legal, corporate development, and government affairs at Dendreon. She has experience in high-growth business development, complex transaction structuring and negotiation, intellectual property and patent portfolio management, regulatory and clinical strategy, as well as public company representation. Ms. Mikail most recently served as senior vice president, corporate development at Savient Pharmaceuticals. Prior to that, Ms. Mikail served as vice president, general counsel and secretary for ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, as well as a member of Eli Lilly’s Transactions Center of Expertise. Previously, Ms. Mikail worked at the law firms of Reed Smith LLP, Lowenstein Sandler PC and Wilmer Hale. Ms. Mikail earned her Bachelor of Arts from Rutgers University and J.D. from Fordham University School of Law.
Ms. Mikail succeeds John E. Osborn, who will remain with Dendreon to assist in the transition and provide advice to Mr. Johnson on selected matters. Mr. Osborn also will be teaching at the University of Washington and serving as a member of the healthcare innovation policy group for the Romney presidential campaign. "We’re grateful to John for his contributions. John joined the company in a critical transitional period following our launch of PROVENGE, and he provided valuable strategic advice and counsel to me and the Board of Directors, while working to strengthen our legal, compliance and policy functions," said Mitchell H. Gold, executive chairman of the Board of Directors.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Home Depot expands executive roles, grants $500K in restricted stock
- Simmons Bank chief data officer Lisa Hunter to retire
- Ingredion names Diego Reynoso as CFO, effective October 2026
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
